PIK3CG and endometrial cancer: 3.3. The Combination of Alpelisib and Eribulin Suppresses the PI3K/AKT Pathway More Effectively Than Monotherapy in Both Paclitaxel-Sensitive and Paclitaxel-Resistant Endometrial Cancer Cells